1. Home
  2. TWST vs COLL Comparison

TWST vs COLL Comparison

Compare TWST & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$40.36

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$47.21

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWST
COLL
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
TWST
COLL
Price
$40.36
$47.21
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$44.67
$51.17
AVG Volume (30 Days)
1.2M
502.7K
Earning Date
02-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$376,572,000.00
$757,067,000.00
Revenue This Year
$15.19
$26.35
Revenue Next Year
$15.10
$3.67
P/E Ratio
N/A
$29.62
Revenue Growth
20.32
26.34
52 Week Low
$23.30
$23.23
52 Week High
$55.33
$50.79

Technical Indicators

Market Signals
Indicator
TWST
COLL
Relative Strength Index (RSI) 71.61 50.34
Support Level $34.55 $45.00
Resistance Level $37.73 $49.17
Average True Range (ATR) 1.79 1.86
MACD 0.59 -0.28
Stochastic Oscillator 93.96 41.90

Price Performance

Historical Comparison
TWST
COLL

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: